{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:34:35Z","timestamp":1790386475262,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical writing support was funded by Alexion, AstraZeneca Rare Disease."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Paroxysmal nocturnal\u202fhemoglobinuria (PNH) is a rare hematological disorder caused by uncontrolled terminal complement activation of blood cells. It is associated with intravascular hemolysis, thromboembolic events, organ damage, impaired quality of life and premature mortality. As there are no PNH registry data from Middle Eastern countries, little is known about its management in the region. This narrative review summarizes available data on the prevalence, characteristics, diagnosis and treatment of PNH in Middle Eastern populations of Arabic origin. A search of PubMed and EMBASE from inception to 31 May 2025 identified 15 relevant publications: five from Saudi Arabia, four from Iran, two from Kuwait, one each from Egypt, Oman, Lebanon, and one reporting a Middle Eastern patient treated in Germany. The estimated incidence rate of PNH in an Omani cohort was 1.9 per 5 million population. Mean and median ages at PNH diagnosis were 38\u00a0years (Iranian retrospective review,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200981) and 22.5\u00a0years (Omani case series,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910), respectively. Where reported, anemia and fatigue were common presenting symptoms. Few publications reported on treatment with C5 inhibitors, although available data indicate that eculizumab generally improves patients\u2019 clinical condition. Uptake and clinical use of ravulizumab in the Middle East remains undocumented. Subject to limitations of the available data, the management approach to PNH in the Middle East appears to be generally consistent with that reported in other regions. However, additional data are required to gain greater insight into the status of PNH and its management in Middle Eastern populations.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01834-5","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T06:45:42Z","timestamp":1756622742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review"],"prefix":"10.1007","volume":"25","author":[{"given":"Mohammed","family":"Almakadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"AlHashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8838","authenticated-orcid":false,"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazzaa","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani Yousif","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"issue":"12","key":"1834_CR1","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","volume":"106","author":"C Parker","year":"2005","unstructured":"Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699\u2013709. https:\/\/doi.org\/10.1182\/blood-2005-04-1717.","journal-title":"Blood"},{"issue":"18","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311. https:\/\/doi.org\/10.1182\/blood-2014-02-522128.","journal-title":"Blood"},{"key":"1834_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3: 17028. https:\/\/doi.org\/10.1038\/nrdp.2017.28.","journal-title":"Nat Rev Dis Primers"},{"key":"1834_CR4","unstructured":"Shah N, Bhatt H. Paroxysmal nocturnal hemoglobinuria. 2023 Jul 31. In: StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"issue":"5","key":"1834_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Soci\u00e9 G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922\u20139. https:\/\/doi.org\/10.3324\/haematol.2013.093161.","journal-title":"Haematologica"},{"issue":"9","key":"1834_CR6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/imj.13160","volume":"46","author":"G Soci\u00e9","year":"2016","unstructured":"Soci\u00e9 G, Schrezenmeier H, Muus P, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. Intern Med J. 2016;46(9):1044\u201353. https:\/\/doi.org\/10.1111\/imj.13160.","journal-title":"Intern Med J"},{"issue":"9","key":"1834_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/imj.13523","volume":"47","author":"AM Almeida","year":"2017","unstructured":"Almeida AM, Bedrosian C, Cole A, et al. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J. 2017;47(9):1026\u201334. https:\/\/doi.org\/10.1111\/imj.13523.","journal-title":"Intern Med J"},{"issue":"7","key":"1834_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, R\u00f6th A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH registry. Ann Hematol. 2020;99(7):1505\u201314. https:\/\/doi.org\/10.1007\/s00277-020-04052-z.","journal-title":"Ann Hematol"},{"issue":"1","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000526979","volume":"146","author":"A Hill","year":"2023","unstructured":"Hill A, de Latour RP, Kulasekararaj AG, et al. Concomitant immunosuppressive therapy and eculizumab use in patients with paroxysmal nocturnal hemoglobinuria: an International PNH Registry analysis. Acta Haematol. 2023;146(1):1\u201313. https:\/\/doi.org\/10.1159\/000526979.","journal-title":"Acta Haematol"},{"issue":"Supplement_1","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2019-125867","volume":"134","author":"JJ Jalbert","year":"2019","unstructured":"Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement_1):3407. https:\/\/doi.org\/10.1182\/blood-2019-125867.","journal-title":"Blood"},{"issue":"2","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.13640","volume":"107","author":"SJ Richards","year":"2021","unstructured":"Richards SJ, Painter D, Dickinson AJ, et al. The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: a retrospective analysis of the UK\u2019s population-based haematological malignancy research network 2004\u20132018. Eur J Haematol. 2021;107(2):211\u20138. https:\/\/doi.org\/10.1111\/ejh.13640.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1834_CR12","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2016.151852","volume":"102","author":"\u00c1 Urbano-Ispizua","year":"2017","unstructured":"Urbano-Ispizua \u00c1, Muus P, Schrezenmeier H, Almeida AM, Wilson A, Ware RE. Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. Haematologica. 2017;102(3):e76\u20139. https:\/\/doi.org\/10.3324\/haematol.2016.151852.","journal-title":"Haematologica"},{"issue":"3","key":"1834_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.24287\/1726-1708-2018-17-3-11-21","volume":"17","author":"AD Kulagin","year":"2018","unstructured":"Kulagin AD, Klimova OU, Dobronravov AV, et al. Paroxysmal nocturnal hemoglobinuria in children and adults: comparative clinical profile and long-term prognosis. Pediatric Hematol Oncol Immunopathol. 2018;17(3):11\u201321. https:\/\/doi.org\/10.24287\/1726-1708-2018-17-3-11-21.","journal-title":"Pediatric Hematol Oncol Immunopathol"},{"issue":"10","key":"1834_CR14","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1172\/JCI74747","volume":"124","author":"W Shen","year":"2014","unstructured":"Shen W, Clemente MJ, Hosono N, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014;124(10):4529\u201338. https:\/\/doi.org\/10.1172\/JCI74747.","journal-title":"J Clin Invest"},{"issue":"1","key":"1834_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1084\/jem.162.1.75","volume":"162","author":"T Kinoshita","year":"1985","unstructured":"Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1985;162(1):75\u201392. https:\/\/doi.org\/10.1084\/jem.162.1.75.","journal-title":"J Exp Med"},{"issue":"1","key":"1834_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/imr.13137","volume":"313","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Frieri C, Urciuoli E, Marano L. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: from a pathogenic mechanism to a therapeutic target. Immunol Rev. 2023;313(1):262\u201378. https:\/\/doi.org\/10.1111\/imr.13137.","journal-title":"Immunol Rev"},{"issue":"13","key":"1834_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","volume":"293","author":"RP Rother","year":"2005","unstructured":"Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653\u201362. https:\/\/doi.org\/10.1001\/jama.293.13.1653.","journal-title":"JAMA"},{"issue":"6","key":"1834_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","volume":"190","author":"CB Xie","year":"2020","unstructured":"Xie CB, Jane-Wit D, Pober JS. Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am J Pathol. 2020;190(6):1138\u201350. https:\/\/doi.org\/10.1016\/j.ajpath.2020.02.006.","journal-title":"Am J Pathol"},{"key":"1834_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101158","volume":"64","author":"A Waheed","year":"2024","unstructured":"Waheed A, Shammo J, Dingli D. Paroxysmal nocturnal hemoglobinuria: review of the patient experience and treatment landscape. Blood Rev. 2024;64: 101158. https:\/\/doi.org\/10.1016\/j.blre.2023.101158.","journal-title":"Blood Rev"},{"issue":"6","key":"1834_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","volume":"97","author":"JW Lee","year":"2013","unstructured":"Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean registry. Int J Hematol. 2013;97(6):749\u201357. https:\/\/doi.org\/10.1007\/s12185-013-1346-4.","journal-title":"Int J Hematol"},{"issue":"2","key":"1834_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3346\/jkms.2016.31.2.214","volume":"31","author":"JH Jang","year":"2016","unstructured":"Jang JH, Kim JS, Yoon SS, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH registry. J Korean Med Sci. 2016;31(2):214\u201321. https:\/\/doi.org\/10.3346\/jkms.2016.31.2.214.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1834_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bjh.17860","volume":"196","author":"RA Brodsky","year":"2022","unstructured":"Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br J Haematol. 2022;196(2):264\u20135. https:\/\/doi.org\/10.1111\/bjh.17860.","journal-title":"Br J Haematol"},{"issue":"1","key":"1834_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13059","volume":"101","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: expert consensus. Eur J Haematol. 2018;101(1):3\u201311. https:\/\/doi.org\/10.1111\/ejh.13059.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1834_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.htct.2020.06.006","volume":"43","author":"RD Can\u00e7ado","year":"2021","unstructured":"Can\u00e7ado RD, Ara\u00fajo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341\u20138. https:\/\/doi.org\/10.1016\/j.htct.2020.06.006.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"17","key":"1834_CR25","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2165\/11208300-000000000-00000","volume":"71","author":"K McKeage","year":"2011","unstructured":"McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327\u201345. https:\/\/doi.org\/10.2165\/11208300-000000000-00000.","journal-title":"Drugs"},{"issue":"12","key":"1834_CR26","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, D\u00fchrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123\u20138. https:\/\/doi.org\/10.1182\/blood-2007-06-095646.","journal-title":"Blood"},{"issue":"6","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MPH.0000000000002178","volume":"43","author":"S Zhou","year":"2021","unstructured":"Zhou S, Dong X, Chen C, et al. Efficacy and safety of eculizumab for paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis. J Pediatr Hematol Oncol. 2021;43(6):203\u201310. https:\/\/doi.org\/10.1097\/MPH.0000000000002178.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"1834_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876136.","journal-title":"Blood"},{"issue":"6","key":"1834_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876805.","journal-title":"Blood"},{"issue":"3","key":"1834_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14712598.2020.1725468","volume":"20","author":"JW Lee","year":"2020","unstructured":"Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther. 2020;20(3):227\u201337. https:\/\/doi.org\/10.1080\/14712598.2020.1725468.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1834_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.11406\/rinketsu.64.9","volume":"64","author":"K Ishiyama","year":"2023","unstructured":"Ishiyama K, Usuki K, Ikezoe T, et al. Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki. 2023;64(1):9\u201317. https:\/\/doi.org\/10.11406\/rinketsu.64.9. (in Japanese).","journal-title":"Rinsho Ketsueki"},{"issue":"3","key":"1834_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.512","volume":"5","author":"ST Rehan","year":"2022","unstructured":"Rehan ST, Hashmi MR, Asghar MS, Tahir MJ, Yousaf Z. Pegcetacoplan - a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria. Health Sci Rep. 2022;5(3): e512. https:\/\/doi.org\/10.1002\/hsr2.512.","journal-title":"Health Sci Rep"},{"issue":"18","key":"1834_CR33","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s40265-022-01809-w.Erratum.In:Drugs2023Jun1","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Pegcetacoplan: a review in paroxysmal nocturnal haemoglobinuria. Drugs. 2022;82(18):1727\u201335. https:\/\/doi.org\/10.1007\/s40265-022-01809-w.Erratum.In:Drugs2023Jun1.","journal-title":"Drugs"},{"issue":"11","key":"1834_CR34","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2029073.","journal-title":"N Engl J Med"},{"issue":"9","key":"1834_CR35","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","volume":"9","author":"RP de Latour","year":"2022","unstructured":"de Latour RP, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648\u201359. https:\/\/doi.org\/10.1016\/S2352-3026(22)00210-1.","journal-title":"Lancet Haematol"},{"issue":"12","key":"1834_CR36","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","volume":"10","author":"JW Lee","year":"2023","unstructured":"Lee JW, Griffin M, Kim JS, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023;10(12):e955\u201365. https:\/\/doi.org\/10.1016\/S2352-3026(23)00315-0.","journal-title":"Lancet Haematol"},{"issue":"23","key":"1834_CR37","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood.2021014868","volume":"139","author":"GF Gerber","year":"2022","unstructured":"Gerber GF, Brodsky RA. Pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood. 2022;139(23):3361\u20135. https:\/\/doi.org\/10.1182\/blood.2021014868.","journal-title":"Blood"},{"issue":"2","key":"1834_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra2201664","volume":"387","author":"R Notaro","year":"2022","unstructured":"Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022;387(2):160\u20136. https:\/\/doi.org\/10.1056\/NEJMra2201664.","journal-title":"N Engl J Med"},{"issue":"11","key":"1834_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","volume":"390","author":"R Peffault de Latour","year":"2024","unstructured":"Peffault de Latour R, R\u00f6th A, Kulasekararaj AG, et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2024;390(11):994\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2308695.","journal-title":"N Engl J Med"},{"issue":"5","key":"1834_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40265-024-02009-4","volume":"84","author":"YY Syed","year":"2024","unstructured":"Syed YY. Iptacopan: first approval. Drugs. 2024;84(5):599\u2013606. https:\/\/doi.org\/10.1007\/s40265-024-02009-4.","journal-title":"Drugs"},{"issue":"12","key":"1834_CR41","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","volume":"106","author":"AM Risitano","year":"2021","unstructured":"Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(12):3188\u201397. https:\/\/doi.org\/10.3324\/haematol.2020.261826.","journal-title":"Haematologica"},{"issue":"5","key":"1834_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40265-024-02023-6","volume":"84","author":"C Kang","year":"2024","unstructured":"Kang C. Danicopan: first approval. Drugs. 2024;84(5):613\u20138. https:\/\/doi.org\/10.1007\/s40265-024-02023-6.","journal-title":"Drugs"},{"issue":"11","key":"1834_CR43","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3324\/haematol.2012.062828","volume":"97","author":"R Peffault de Latour","year":"2012","unstructured":"Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666\u201373. https:\/\/doi.org\/10.3324\/haematol.2012.062828.","journal-title":"Haematologica"},{"issue":"3","key":"1834_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/tropej\/48.3.132","volume":"48","author":"S Rizk","year":"2002","unstructured":"Rizk S, Ibrahim IY, Mansour IM, Kandil D. Screening for paroxysmal nocturnal hemoglobinuria (PNH) clone in Egyptian children with aplastic anemia. J Trop Pediatr. 2002;48(3):132\u20137. https:\/\/doi.org\/10.1093\/tropej\/48.3.132.","journal-title":"J Trop Pediatr"},{"issue":"6","key":"1834_CR45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cyto.b.21317","volume":"88","author":"N AlGhasham","year":"2015","unstructured":"AlGhasham N, Abulkhair Y, Khalil S. Flow cytometry screening for paroxysmal nocturnal hemoglobinuria: A single-center experience in Saudi Arabia. Cytometry B Clin Cytom. 2015;88(6):389\u201394. https:\/\/doi.org\/10.1002\/cyto.b.21317.","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"1834_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/hon.2367","volume":"35","author":"H Kamranzadeh Fumani","year":"2017","unstructured":"Kamranzadeh Fumani H, Zokaasadi M, Kasaeian A, et al. Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: a retrospective single-center study. Hematol Oncol. 2017;35(4):935\u20138. https:\/\/doi.org\/10.1002\/hon.2367.","journal-title":"Hematol Oncol"},{"issue":"2","key":"1834_CR47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/sjmms.sjmms_4_20","volume":"9","author":"YM Al-Dosari","year":"2021","unstructured":"Al-Dosari YM, Al-Zahrani H, Al-Mohareb F, Hashmi S. Pregnancy with paroxysmal nocturnal hemoglobinuria: a case series with review of the literature. Saudi J Med Med Sci. 2021;9(2):178\u201389. https:\/\/doi.org\/10.4103\/sjmms.sjmms_4_20.","journal-title":"Saudi J Med Med Sci"},{"issue":"2","key":"1834_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.hemonc.2020.11.001","volume":"15","author":"N AlMozain","year":"2022","unstructured":"AlMozain N, Mashi A, Alneami Q, et al. Spectrum of myelodysplastic syndrome in patients evaluated for cytopenia(s). A report from a reference centre in Saudi Arabia. Hematol Oncol Stem Cell Ther. 2022;15(2):39\u201344. https:\/\/doi.org\/10.1016\/j.hemonc.2020.11.001.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"1834_CR49","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2022.13","volume":"37","author":"AZ Al-Riyami","year":"2022","unstructured":"Al-Riyami AZ, Al-Kindi Y, Al-Qassabi J, et al. Clinicopathological profile of paroxysmal nocturnal hemoglobinuria among Omani patients: a case series. Oman Med J. 2022;37(4): e405. https:\/\/doi.org\/10.5001\/omj.2022.13.","journal-title":"Oman Med J"},{"issue":"2","key":"1834_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jha2.410","volume":"3","author":"M Jahangirpour","year":"2022","unstructured":"Jahangirpour M, Vahedi A, Baghdadi H, et al. Paroxysmal nocturnal haemoglobinuria, diagnosis and haematological findings, first report from Iran, model for developing countries. EJHaem. 2022;3(2):335\u201340. https:\/\/doi.org\/10.1002\/jha2.410.","journal-title":"EJHaem"},{"issue":"2","key":"1834_CR51","first-page":"147","volume":"9","author":"A Al-Harbi","year":"1998","unstructured":"Al-Harbi A, Alfurayh O, Sobh M, Akhtar M, Tashkandy MA, Shaaban A. Paroxysmal nocturnal hemoglobinuria and renal failure. Saudi J Kidney Dis Transpl. 1998;9(2):147\u201351.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"4","key":"1834_CR52","first-page":"255","volume":"50","author":"A Mooraki","year":"1998","unstructured":"Mooraki A, Boroumand B, Mohammad Zadeh F, Ahmed SH, Bastani B. Acute reversible renal failure in a patient with paroxysmal nocturnal hemoglobinuria. Clin Nephrol. 1998;50(4):255\u20137.","journal-title":"Clin Nephrol"},{"issue":"4","key":"1834_CR53","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/003655900750042068","volume":"134","author":"P Khajehdehi","year":"2000","unstructured":"Khajehdehi P. Reversible acute renal failure with prolonged oliguria and gross hematuria in a case of paroxysmal nocturnal hemoglobinuria. Scand J Urol Nephrol. 2000;134(4):284\u20136. https:\/\/doi.org\/10.1080\/003655900750042068.","journal-title":"Scand J Urol Nephrol"},{"issue":"8","key":"1834_CR54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0961203308100558","volume":"18","author":"A Gupta","year":"2009","unstructured":"Gupta A, Al Fulaij R, Gupta RK, Gupta G, Marouf R. Development of paroxysmal nocturnal haemoglobinuria in systemic lupus erythematosus: an unusual cause of portal vein thrombosis. Lupus. 2009;18(8):743\u20136. https:\/\/doi.org\/10.1177\/0961203308100558.","journal-title":"Lupus"},{"issue":"3","key":"1834_CR55","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2015.5927","volume":"7","author":"HA Al-Jafar","year":"2015","unstructured":"Al-Jafar HA, AlDallal SM, Askar HA, Aljeraiwi AM, Al-Alansari A. Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria. Hematol Rep. 2015;7(3): 5927. https:\/\/doi.org\/10.4081\/hr.2015.5927.","journal-title":"Hematol Rep"},{"issue":"3","key":"1834_CR56","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4103\/1319-2442.157384","volume":"26","author":"DT Boqari","year":"2015","unstructured":"Boqari DT, Al Faraj S, Arafah M, et al. Herb-induced acute bone marrow intoxication and interstitial nephritis superimposing glomerular C1q deposition in a patient with paroxysmal nocturnal hemoglobinuria. Saudi J Kidney Dis Transpl. 2015;26(3):572\u20139. https:\/\/doi.org\/10.4103\/1319-2442.157384.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"Supplement 3","key":"1834_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000479566","volume":"40","author":"M Alsara","year":"2017","unstructured":"Alsara M, Alashkar F, Baum J, et al. Transfusion-dependent breakthrough hemolysis accompanied by an acute Budd-Chiari Syndrome (BCS) in a pregnant patient with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab. Oncol Res Treat. 2017;40(Supplement 3):157. https:\/\/doi.org\/10.1159\/000479566.","journal-title":"Oncol Res Treat"},{"key":"1834_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102641","volume":"93","author":"K Jarrah","year":"2022","unstructured":"Jarrah K, Al Mahmasani L, Atoui A, Bou-Fakhredin R, Taher AT. Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination. Blood Cells Mol Dis. 2022;93: 102641. https:\/\/doi.org\/10.1016\/j.bcmd.2021.102641.","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"1834_CR59","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1590\/1806-9282.64.12.1139","volume":"64","author":"\u00caS Macedo","year":"2018","unstructured":"Macedo \u00caS, Parente Filho SLA, Pro JDZ, et al. Renal involvement in paroxysmal nocturnal haemoglobinuria: a brief review of the literature. Rev Assoc Med Bras. 2018;64(12):1139\u201346. https:\/\/doi.org\/10.1590\/1806-9282.64.12.1139.","journal-title":"Rev Assoc Med Bras"},{"issue":"5","key":"1834_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051261","volume":"9","author":"G Gembillo","year":"2020","unstructured":"Gembillo G, Siligato R, Cernaro V, Santoro D. Complement inhibition therapy and dialytic strategies in paroxysmal nocturnal hemoglobinuria: the nephrologist\u2019s opinion. J Clin Med. 2020;9(5): 1261. https:\/\/doi.org\/10.3390\/jcm9051261.","journal-title":"J Clin Med"},{"issue":"2","key":"1834_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790.","journal-title":"Br J Haematol"},{"issue":"1","key":"1834_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1753495X211019899","volume":"15","author":"JE Manning","year":"2022","unstructured":"Manning JE, Anderson RM, Hill A, Zeidan D, Ciantar E. Pregnancy outcomes in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. Obstet Med. 2022;15(1):45\u20139. https:\/\/doi.org\/10.1177\/1753495X211019899.","journal-title":"Obstet Med"},{"issue":"Supplement 1","key":"1834_CR63","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1182\/blood-2024-209857","volume":"144","author":"B Hoechsmann","year":"2024","unstructured":"Hoechsmann B, Leopold W, Schneider A, Koerper S, Kalhammer U, Schrezenmeier H. Ravulizumab in pregnant women with paroxysmal nocturnal hemoglobinuria (PNH) \u2212 favourable experience from a retrospective case series. Blood. 2024;144(Supplement 1):5251. https:\/\/doi.org\/10.1182\/blood-2024-209857.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01834-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:42Z","timestamp":1764917562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01834-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01834-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohammed Almakadi has received honoraria from AstraZeneca, Novartis, Novo Nordisk, and Sobi. Noura AlHashim has no conflicts of interest to declare. Murtadha Al-Khabori has received honoraria from AstraZeneca and Sobi. Hazzaa Alzahrani has received honoraria from AstraZeneca, Novartis, Novo Nordisk, and Sobi. Hani Yousif\u00a0Osman has received honoraria from AbbVie, AstraZeneca, BMS, Janssen, Novartis, Sanofi and Sobi. Mervat Mattar has received fees from AstraZeneca, BMS, Janssen, Novartis, and Pfizer. Ahmed Sabah has received speaker fees from AstraZeneca and Janssen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"310"}}